Medicare Enrolled
Dr. Deepak Muthappa, M.D.
Family Medicine · Paris, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Muthappa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Muthappa? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Muthappa
Dr. Deepak Muthappa is a family medicine in Paris, TX, with 12 years in practice. Based on federal Medicare data, Dr. Muthappa performed 11,142 Medicare services across 4,687 unique beneficiaries.
Between the years covered by Open Payments, Dr. Muthappa received a total of $62,905 from 58 pharmaceutical and/or device companies across 936 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in family medicine. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Muthappa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 12 years in practice▲ Top 1% volume in TX$ $62,905 industry payments
Medicare Practice Summary
Medicare Utilization ↗11,142
Medicare services
Top 1% in TX for family medicine
4,687
Unique beneficiaries
$57
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~928 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Chronic care management, first 20 min/month | 2,732 | $47 | $128 |
| Office visit, established patient (30-39 min) | 2,288 | $84 | $155 |
| Chronic care management, additional 20 min/month | 1,374 | $36 | $97 |
| Annual depression screening | 364 | $18 | $35 |
| Annual wellness visit, follow-up | 348 | $124 | $200 |
| Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | 337 | $53 | $141 |
| Office visit, established patient, complex (40-54 min) | 279 | $131 | $210 |
| Nursing facility visit, moderate complexity | 252 | $78 | $132 |
| Drug injection, under skin or into muscle | 210 | $10 | $45 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 199 | $101 | $269 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 181 | $29 | $75 |
| Ultrasound study of arm and leg arteries | 166 | $43 | $529 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 149 | $27 | $497 |
| Test to examine how well the lungs exchange gases | 149 | $41 | $299 |
| Test to determine lung volumes using sensors | 146 | $40 | $349 |
| Office visit, established patient (20-29 min) | 144 | $58 | $105 |
| Steroid injection (triamcinolone) | 125 | $1 | $25 |
| Office visit, established patient (10-19 min) | 114 | $40 | $75 |
| Ultrasound of heart, follow-up | 104 | $44 | $958 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 104 | $17 | $311 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 104 | $16 | $249 |
| Ultrasound of aorta, vena cava, groin vessels or bypass grafts | 102 | $57 | $1,013 |
| Electrocardiogram (EKG), 12-lead | 98 | $9 | $134 |
| Automated urinalysis | 93 | $2 | $10 |
| Ultrasound of one side of head and neck blood flow | 88 | $74 | $1,074 |
| Ceftriaxone antibiotic injection | 77 | $0 | $35 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 71 | $38 | $100 |
| Administration of vaccine | 70 | $14 | $50 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 68 | $26 | $43 |
| Flu vaccine, quadrivalent | 61 | $73 | $85 |
| Retinal photography (fundus photo) | 59 | $25 | $189 |
| Injection, lidocaine hcl for intravenous infusion, 10 mg | 53 | $0 | $10 |
| Joint injection, major joint | 50 | $43 | $175 |
| New patient office visit (45-59 min) | 50 | $70 | $238 |
| Transitional care management services for problem of high complexity | 41 | $211 | $564 |
| Ultrasound scan of head and neck soft tissue | 40 | $83 | $1,230 |
| Evaluation of use of breathing device | 38 | $13 | $50 |
| Transitional care management services for problem of at least moderate complexity | 32 | $148 | $416 |
| Subsequent nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | 28 | $110 | $197 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $15 | $40 |
| Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | 18 | $207 | $550 |
| Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | 18 | $96 | $191 |
| Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 2.1-3.0 cm | 17 | $183 | $450 |
| New patient office visit, complex (60-74 min) | 17 | $143 | $300 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 17 | $158 | $275 |
| Testing for presence of drug, read by direct observation | 15 | $12 | $25 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 14 | $156 | $241 |
| Removal of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | 12 | $151 | $600 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.3% high complexity
7.7% medium
89.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$62,905
Total received (2018-2024)
Avg $8,986/year across 7 years
Top 0% in TX for family medicine
58
Companies
936
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$52,341 (83.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,564 (16.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$13,733
2023$9,594
2022$12,443
2021$14,556
2020$9,547
2019$1,763
2018$1,268
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$31,620
Allergan, Inc.
$11,302
AbbVie Inc.
$9,419
Novo Nordisk Inc
$1,534
GlaxoSmithKline, LLC.
$1,327
AstraZeneca Pharmaceuticals LP
$1,087
Lilly USA, LLC
$693
Mylan Specialty L.P.
$578
Merck Sharp & Dohme Corporation
$556
PFIZER INC.
$453
Sunovion Pharmaceuticals Inc.
$353
Amgen Inc.
$324
Allergan Inc.
$322
Janssen Pharmaceuticals, Inc
$288
Otsuka America Pharmaceutical, Inc.
$286
SANOFI-AVENTIS U.S. LLC
$283
Amarin Pharma Inc.
$216
Boehringer Ingelheim Pharmaceuticals, Inc.
$216
Bayer HealthCare Pharmaceuticals Inc.
$162
Horizon Therapeutics plc
$159
AIMMUNE THERAPEUTICS, INC.
$133
Astellas Pharma US Inc
$132
Bayer Healthcare Pharmaceuticals Inc.
$129
Novartis Pharmaceuticals Corporation
$119
Takeda Pharmaceuticals U.S.A., Inc.
$108
Merck Sharp & Dohme LLC
$105
Eisai Inc.
$82
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$75
Currax Pharmaceuticals LLC
$61
Biohaven Pharmaceuticals, Inc.
$60
ITI, Inc.
$58
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)
$51
Dexcom, Inc.
$51
Philips North America LLC
$46
Teleflex LLC
$39
Exact Sciences Corporation
$38
Almatica Pharma LLC
$36
Biohaven Pharmaceutical Holding Company Ltd.
$34
NESTLE HEALTHCARE NUTRITION INC.
$33
Insulet Corporation
$31
Shield Therapeutics Inc
$29
Avanir Pharmaceuticals, Inc.
$28
Nestle HealthCare Nutrition Inc.
$25
SCPHARMACEUTICALS INC.
$22
Inspire Medical Systems, Inc.
$22
EISAI INC.
$19
US WorldMeds, LLC
$15
NOVARTIS PHARMACEUTICALS CORPORATION
$15
SHIELD THERAPEUTICS INC
$15
Celgene Corporation
$15
E.R. Squibb & Sons, L.L.C.
$14
Axsome Therapeutics, Inc.
$13
Kowa Pharmaceuticals America, Inc.
$13
Purdue Pharma L.P.
$13
Teva Pharmaceuticals USA, Inc.
$13
Upsher-Smith Laboratories LLC
$13
Philips Electronics North America Corporation
$12
Esperion Therapeutics, Inc.
$12
Top 3 companies account for 83.2% of total payments
Associated products mentioned in payments ›
(8874) inCourage · (CK7) Extended Holter · ACCRUFER · AIRSUPRA · AJOVY · ANORO · ANORO ELLIPTA · APTIOM · AREXVY · Aimovig · Auvelity · BASAGLAR · BELSOMRA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · BYSTOLIC · CAPLYTA · CHANTIX · COLOGUARD · CONTRAVE · CREON · Cologuard Collection Kit · DEXCOM G7 GSS (161) · Dayvigo · Dexcom G6 Transmitter · Dymista · ELIQUIS · EMGALITY · ENTRESTO · FARXIGA · FASENRA · FUROSCIX · INSPIRE · INVOKANA · JANUMET · JANUMET XR · JANUVIA · JARDIANCE · KRYSTEXXA · Kerendia · LINZESS · LOKELMA · LONHALA MAGNAIR · LOREEV XR · LYRICA · Leqembi · Lucemyra/Lofexidine · MOUNJARO · MYRBETRIQ · Myrbetriq · NEXLETOL · NUCALA · NUEDEXTA · NURTEC ODT · Omnipod · Otezla · Ozempic · Perforomist · QULIPTA · REXULTI · RYBELSUS · Repatha · Rybelsus · SEGLENTIS · SIVEXTRO · SOLIQUA 100/33 · SPIRIVA RESPIMAT · SPRAVATO · STEGLATRO · STIOLTO RESPIMAT · SYMBICORT · SYMPROIC · Saxenda · TOSYMRA SUMATRIPTAN NASAL SPRAY · TOUJEO · TRELEGY ELLIPTA · TRINTELLIX · TRULICITY · Tresiba · Trintellix · UBRELVY · UroLift System · Utibron · VIAGRA · VIBERZI · VIIBRYD · VRAYLAR · VYVANSE · Vascepa · Veozah · Victoza · Wegovy · XARELTO · XIFAXAN · YUPELRI · Yupelri · ZENPEP
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (83%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in family medicine and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 0% for family medicine in TX.
Equivalent to $565 per 100 Medicare services performed
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Muthappa is a clinical cardiology specialist, with above-average Medicare volume (top 1% in TX), and high industry engagement (speaking/promotional, top 0%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Muthappa experienced with chronic care management, first 20 min/month?
Based on Medicare claims data, Dr. Muthappa performed 2,732 chronic care management, first 20 min/month services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Muthappa receive payments from pharmaceutical companies?
Yes. Dr. Muthappa received a total of $62,905 from 58 companies across 936 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Muthappa's costs compare to other family medicines in Paris?
Dr. Muthappa's average Medicare payment per service is $57. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Muthappa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Family Medicine
Common procedures, typical costs, and what industry payments mean in family medicine.
Same specialty & city
Family Medicines in Paris
Browse family medicines in Paris ranked by procedure volume and transparency data.
Highest volume
Top Family Medicines in TX
Family Medicines ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Family Medicines in TX
Which TX family medicines receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC..
By company
Allergan, Inc. Payments to Doctors
See all physicians who received payments from Allergan, Inc..
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology